Veradermics Prices Upsized IPO, Raises $256.3 Million

IPO Pricing and Capital Raised

Veradermics, Incorporated has announced the pricing of its upsized initial public offering of 15,077,647 common stock shares at $17.00 per share. The company expects to generate approximately $256.3 million in gross proceeds from the offering before deducting underwriting discounts and associated expenses.

Company and Market Overview

Veradermics is a biopharmaceutical firm focused on developing therapeutics for aesthetic and dermatological conditions. Its lead program, VDPHL01, is an oral, extended-release minoxidil formulation intended as a non-hormonal treatment for pattern hair loss in both men and women.

Stock Debut and Offering Details

The company's common stock is expected to commence trading on the New York Stock Exchange under the ticker symbol 'MANE' on February 4, 2026. The offering is anticipated to close on February 5, 2026. Jefferies, Leerink Partners, Citigroup, and Cantor are acting as joint book-running managers. Underwriters have a 30-day option to purchase up to an additional 2,261,647 shares.

Summary

This successful IPO provides Veradermics with significant capital to advance its clinical programs. Investor response following the stock's market debut will be a key indicator of confidence in its specialized therapeutic pipeline for dermatological conditions.

FAQ

Q: What is the ticker symbol for Veradermics, Incorporated?
A: The company will trade on the NYSE under the ticker symbol MANE.

Q: How much capital did Veradermics raise in its IPO?
A: The company raised approximately $256.3 million in gross proceeds.

Source: investing.com